Why did 1541.HK stock fall pre-market?

The pre-market drop of **-20.07%** reflects heavy selling and volume spike. Causes often include clinical or funding worries, stop-losses, or sector weakness. For definitive reasons, review company announcements and HKEX filings for news or management updates.

What is Meyka AI's outlook for 1541.HK stock?

Meyka AI's forecast model projects a yearly price of **HK$10.81**, implying **+129.91%** versus **HK$4.70**. The model notes clinical and funding sensitivity; projections are model-based and not guarantees.

Is 1541.HK stock a buy after the drop?

Meyka AI currently grades 1541.HK **66.62/100 (B, HOLD)**. Given negative EPS and cash burn, a buy decision should hinge on upcoming clinical milestones and funding clarity. Consider risk tolerance and position sizing.

What key ratios should investors watch for 1541.HK stock?

Monitor EPS (**-0.94**), price-to-sales (**16.43**), price-to-book (**3.66**), current ratio (**3.33**), and operating cash flow per share (**-0.33**). These indicate valuation, liquidity, and burn pace.

HK Stocks

1541.HK ImmuneOnco (HKSE) down 20% to HK$4.70 pre-market: watch cash runway

ByHuzaifa Zahoor January 21, 2026

The 1541.HK stock plunged 20.07% in pre-market trade to HK$4.70, signalling heavy selling after session-open weakness in Hong Kong. Volume is elevated at 5,715,800.00 shares versus an average of 1,520,430.00, underlining active liquidation. ImmuneOnco Biopharmaceuticals (1541.HK) trades on the HKSE; the move follows wide dispersion from its 50-day average of HK$6.63 and its 200-day average of HK$9.59. We use Meyka AI real-time tools to connect valuations, clinical-stage risk, and sector trends for a concise pre-market top losers read